Drug Trial Radar · NCT06853444
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
Mar 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Shanghai Escugen Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
ESG206Drug
Administered via intravenous (IV) infusion
ESG206Drug
Administered via intravenous (IV) infusion
ESG206Drug
Administered via intravenous (IV) infusion
ESG206Drug
Administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse EventsTime frame: Up to 24 weeks.
- Confirmed response rateTime frame: Between Week 1 Day 1 and Week 25 Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.